Development of a national protocol to screen Dutch cancer survivors on late cancer treatment effects.
OBJECTIVE
The development of a national protocol to formalize the screening of Dutch cancer survivors on potential late cancer treatment effects and the medical terminology used in describing the patient follow up procedures.


METHODS
A combined evidence-based and qualitative approach, the Glaser's State of the Art Strategy, was used to reach consensus on how to screen Dutch cancer survivors on late cancer treatment effects. A core working group set up a first proposal of a screening protocol and a handbook of medical term definitions by incorporating available research evidence (1980-2003), clinical expertise and definitions from Dutch medical dictionaries and textbooks. External experts reviewed this proposal in a cycle of two postal and two discussion rounds. The follow-up procedures and medical term definitions described in the draft screening protocol were to be accepted if consensus among external experts was > or =50%.


RESULTS
A protocol for screening cancer survivors on late cancer treatment effects was developed describing the follow-up procedures for cancer survivors according to previous therapeutic exposures. Four hundred and twenty one medical terms were used in describing these follow-up procedures. One hundred and fifteen of these terms were classified as multi-interpretable and 101 of these terms were defined. No definitions could be found for the remaining 14 medical terms.


CONCLUSIONS
We succeeded in reaching consensus throughout The Netherlands on a protocol to screen cancer survivors on late cancer treatment effects. This protocol is now in use by all Dutch outpatient clinics and warrants that the screening of cancer survivors is consistent across The Netherlands. The screening protocol specifies in detail how screening of cancer survivors should take place and can therefore be used by clinicians who were not involved in the consensus study.
Jaspers
M W M
MW
Department of Medical Informatics, University of Amsterdam/Academic Medical Center, The Netherlands. m.w.jaspers@amc.uva.nl
Van den Bos
C
C
Heinen
R C
RC
Bakker
P J M
PJ
Geenen
M M
MM
Kremer
L C
LC
Van Leeuwen
F
F
Caron
H N
HN
D024221:Antineoplastic Protocols; D019317:Evidence-Based Medicine; D006801:Humans; D008403:Mass Screening / Q000592:standards*; D016347:Medical Records Systems, Computerized; D009369:Neoplasms / Q000628:therapy*; D009426:Netherlands; D010045:Outpatients; D010372:Pediatrics; D011785:Quality Assurance, Health Care; D013534:Survival; D016896:Treatment Outcome